<DOC>
	<DOCNO>NCT00287300</DOCNO>
	<brief_summary>The purpose study compare efficacy safety three treatment regimens prevention malaria pregnancy .</brief_summary>
	<brief_title>Efficacy Safety Azithromycin Artesunate Pregnant Women</brief_title>
	<detailed_description>Malaria infection pregnancy pose substantial risk mother , fetus , neonate . Prevention malaria pregnancy vital decrease maternal child mortality Africa . There data study show intermittent preventive treatment ( IPT ) two dos sulfadoxine-pyrimethamine ( SP ) safe , efficacious , effective prevent maternal anemia , placental parasitemia , LBW . Resistance SP , however , increase rapidly Africa urgent need find alternative effective , safe affordable drug treatment prevention malaria pregnancy . The investigator conduct trial determine efficacy safety azithromycin artesunate combine sulphadoxine-pyrimethamine treatment malaria pregnancy.Pregnant woman 14 26 week gestation P. falciparum parasitemia peripheral blood film randomly assign 3 treatment group receive two dos : ( 1 ) SP ( 3 tablet ) ; ( 2 ) SP azithromycin ( 1gram/day x 2 day ) ( 3 ) SP artesunate 200mg/day 3 day ) . The two dos study drug administer approximately 4 week apart . All study drug take observation.Blood sample collect day 1 , 2 , 3 , 7 14 treatment visit woman present symptom malaria . The woman also give insecticide-treated net ( ITN ) follow delivery . Adverse effect assess scheduled visit , unscheduled visit study , delivery . Peripheral placental blood film placental biopsy prepare delivery . Newborns weigh , examine , gestational age determine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>peripheral malaria parasitemia sign informed consent age 1549 year mother felt movement foetus ( quicken ) fetal age least 14 26 complete gestation week maternal availability followup entire period study know maternal tuberculosis , diabetes , kidney disease , liver disease mental disorder may affect comprehension study success followup twin pregnancy pregnancy complication evident enrollment visit ( moderate severe oedema , blood Hb concentration &lt; 7 g / dl , systolic blood pressure ( BP ) &gt; 160 mmHg diastolic BP &gt; 100 mmHg ) prior receipt azithromycin current pregnancy receipt antimalarial within 28 day enrollment know allergy drug contain sulfonamide , macrolides pyrimethamine history anaphylaxis history serious allergic reaction substance , require emergency medical care history hepatitis jaundice concurrent participation clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Artesunate</keyword>
</DOC>